Clinically approved combination immunotherapy: Current status, limitations, and future perspective

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Combination immunotherapy is a first-line treatment for several cancers, including hepatocellular carcinoma (HCC).
• Atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF) combination therapy demonstrates significant clinical efficacy in unresectable HCC.
• This combination improves overall survival, progression-free survival, and objective response rates compared to sorafenib.

Purpose of the Study:

• To review current combination immunotherapies and their immune mechanisms.
• To analyze limitations of atezolizumab plus bevacizumab therapy in HCC.
• To propose approaches for overcoming these limitations and optimizing treatment.

Main Methods:

• Literature review of clinically approved combination immunotherapies.
• Analysis of immune mechanisms underlying combination therapy.
• Perspective analysis of treatment limitations and future directions.

Main Results:

• Atezolizumab plus bevacizumab offers unprecedented efficacy in advanced HCC.
• This combination improves multiple clinical endpoints compared to sorafenib.
• Limitations include patient selection, fixed-dose regimen, and lack of predictive biomarkers.

Conclusions:

• Combination immunotherapy, particularly atezolizumab plus bevacizumab, is a landmark in HCC treatment.
• Further research is essential to refine patient selection, personalize dosing, and develop predictive biomarkers.
• Optimizing combination immunotherapy requires addressing current limitations for enhanced efficacy and safety.